News FDA experts to vote on Spark's groundbreaking gene therapy Luxturna could be single life-changing injection
News Spark files revolutionary gene therapy with FDA Luxturna granted six-month priority review by FDA.
News Submission completed, Spark sets sight on first ever US gene... Spark Therapeutics has completed the rolling submission of gene therapy product voretigene neparvovec, for patients with a rare genetic form of blindness.
News Spark and Pfizer's haemophilia gene therapy gets European PR... Decision based on promising data from ongoing phase 1/2 trial.
News Spark reassures on safety of haemophilia gene therapy Study of nine patients produce encouraging results
News Spark’s gene therapy shows great promise in restoring sight Philadelphia-based company could be frontrunner in gene therapy
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
